Adenoviruses-mediated RNA interference targeting cytosolic phospholipase A2α attenuates focal ischemic brain damage in mice

Wu,Huijun; Liu,Hui; Zuo,Fengtong; Zhang,Lihua

doi:10.3892/mmr.2018.8610

Adenoviruses-mediated RNA interference targeting cytosolic phospholipase A2α attenuates focal ischemic brain damage in mice

Authors:
- Huijun Wu
- Hui Liu
- Fengtong Zuo
- Lihua Zhang
View Affiliations

Affiliations: Department of Neurology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
Published online on: February 15, 2018 https://doi.org/10.3892/mmr.2018.8610
Pages: 5601-5610
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cerebral ischemia injury is a clinical, frequently occurring disease, which causes a heavy burden on society and families. It has been demonstrated that cytosolic phospholipase A2α (cPLA2α) is significant in neurological injury caused by ischemic brain injury, and inhibition of cPLA2α may reduce stroke injury. In the present study, the role of cPLA2α was investigated in a mouse model of middle cerebral artery occlusion and/or reperfusion (MCAO/R) using an effective cPLA2α inhibitor and adenoviruses‑mediated RNA interference. The most effective recombinant adenovirus encoding cPLA2α small interfering RNA (pAd‑siRNA‑cPLA2α) was constructed and selected. MCAO/R surgery is used to construct the model of focal ischemic brain damage in mice. Adenoviruses‑mediated RNA interference targeting cPLA2α was administered by stereotactic surgery 2 h before the MCAO/R. The expression/activity of cPLA2α and cPLA2α‑derived injurious lipid mediators was assessed. pAd‑siRNA‑cPLA2α‑treated animals (RNA interference; RNAi group) were compared with pAd-siRNA-control-treated animals (negative group) with regard to neurological deficit, motor function, pathological changes, apoptosis, and infarct volume. The RNAi group animals reduced the expression level of cPLA2α, as determined by western blotting and reverse transcription‑quantitative polymerase chain reaction, the improvement of locomotor function was evaluated by rotarod test, and the decrease of apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick end‑labeling staining. The decreased infarct areas were evaluated by 2,3,5‑triphenyltetrazolium chloride staining. The expression levels of prostaglandin E2, leukotrienes B4, lysophosphatidylcholine and free fatty acids were reduced in the RNAi group when compared with the negative control group. Thus, the data indicates that the expression level of cPLA2α was effectively controlled by pAd‑siRNA‑cPLA2α treatment. pAd‑siRNA‑cPLA2α treatment, in reducing the levels of inflammatory factors, neurological deficit and tissue damage, represents an effective potential therapeutic strategy. pAd‑siRNA‑cPLA2α reduces cPLA2α expression levels with long‑term efficacy, thereby improving functional deficits and effectively attenuating ischemic brain damage. Thus, pAd‑siRNA‑cPLA2α shows potential value for therapeutic evaluation in ischemic brain damage.

View Figures

View References

1	Arai K, Ikegaya Y, Nakatani Y, Kudo I, Nishiyama N and Matsuki N: Phospholipase A2 mediates ischemic injury in the hippocampus: A regional difference of neuronal vulnerability. In Eur J Neurosci. 13:2319–2323. 2001. View Article : Google Scholar
2	Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA and Sapirstein A: Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 390:622–625. 1997. View Article : Google Scholar : PubMed/NCBI
3	Brady KM, Texel SJ, Kishimoto K, Koehler RC and Sapirstein A: Cytosolic phospholipase A alpha modulates NMDA neurotoxicity in mouse hippocampal cultures. Eur J Neurosci. 24:3381–3386. 2006. View Article : Google Scholar : PubMed/NCBI
4	Ward NC, Croft KD, Blacker D, Hankey GJ, Barden A, Mori TA, Puddey IB and Beer CD: Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci (Lond). 121:501–507. 2011. View Article : Google Scholar : PubMed/NCBI
5	Moskowitz MA, Lo EH and Iadecola C: The science of stroke: Mechanisms in search of treatments. Neuron. 67:181–198. 2010. View Article : Google Scholar : PubMed/NCBI
6	Menschikowski M, Hagelgans A and Siegert G: Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 79:1–33. 2006. View Article : Google Scholar : PubMed/NCBI
7	Gabryel B, Chalimoniuk M, Stolecka A and Langfort J: Activation of cPLA2 and sPLA2 in astrocytes exposed to simulated ischemia in vitro. Cell Biol Int. 31:958–965. 2007. View Article : Google Scholar : PubMed/NCBI
8	Williams SD and Gottlieb RA: Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. Biochem J. 362:23–32. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kishimoto K, Li RC, Zhang J, Klaus JA, Kibler KK, Doré S, Koehler RC and Sapirstein A: Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice. J Neuroinflammation. 7:422010.PubMed/NCBI
10	Shen Y, Kishimoto K, Linden DJ and Sapirstein A: Cytosolic phospholipase A(2) alpha mediates electrophysiologic responses of hippocampal pyramidal neurons to neurotoxic NMDA treatment. Proc Natl Acad Sci USA. 104:pp. 6078–6083. 2007; View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Barasch N, Li RC and Sapirstein A: Inhibition of cytosolic phospholipase A(2) alpha protects against focal ischemic brain damage in mice. Brain Res. 1471:129–137. 2012. View Article : Google Scholar : PubMed/NCBI
12	Leung RK and Whittaker PA: RNA interference: From gene silencing to gene-specific therapeutics. Pharmacol Ther. 107:222–239. 2005. View Article : Google Scholar : PubMed/NCBI
13	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
14	Dykxhoorn DM and Lieberman J: The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 56:401–423. 2005. View Article : Google Scholar : PubMed/NCBI
15	Morris KV and Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
16	Oualikene W, Lamoureux L, Weber JM and Massie B: Protease-deleted adenovirus vectors and complementing cell lines: Potential applications of single-round replication mutants for vaccination and gene therapy. Hum Gene Ther. 11:1341–1353. 2000. View Article : Google Scholar : PubMed/NCBI
17	Abea K, Setoguchib Y, Hayashia T and Itoyama Y: In vivo adenovirus-mediated gene transfer and the expression in ischemic and reperfused rat brain. Brain Res. 763:191–201. 1997. View Article : Google Scholar : PubMed/NCBI
18	Shimizu M, Matsumoto Y, Kurosawa T, Azuma C, Enomoto M, Nakamura H, Hirabayashi T, Kaneko M, Okuma Y and Murayama T: Release of arachidonic acid induced by tumor necrosis factor-alpha in the presence of caspase inhibition: Evidence for a cytosolic phospholipase A2alpha-independent pathway. Biochem Pharmacol. 75:1358–1369. 2008. View Article : Google Scholar : PubMed/NCBI
19	Shen C, Buck AK, Liu X, Winkler M and Reske SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539:111–114. 2003. View Article : Google Scholar : PubMed/NCBI
20	Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd. Cold Spring Harbor Laboratory Press; New York: 1989
21	National Research Council, . Guide for the Care and Use of Laboratory Animals. The National Academies Press; Washington DC: 1996, https://doi.org/10.17226/5140September 6–2014
22	Zhang J, Barasch N, Li RC and Sapirstein A: Inhibition of cytosolic phospholipase A(2) alpha protects against focal ischemic brain damage in mice. Brain Res. 1471:129–137. 2012. View Article : Google Scholar : PubMed/NCBI
23	Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI
24	Khan M, Singh J and Singh I: Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem. 106:1766–1779. 2008.PubMed/NCBI
25	Khan M, Contreras M and Singh I: Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes. J Endotoxin Res. 6:41–50. 2000. View Article : Google Scholar : PubMed/NCBI
26	Weerheim AM, Kolb AM, Sturk A and Nieuwland R: Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem. 302:191–198. 2002. View Article : Google Scholar : PubMed/NCBI
27	Weissman L, Jo DG, Sorensen MM, de Souza-Pinto NC, Markesbery WR, Mattson MP and Bohr VA: Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res. 35:5545–5555. 2007. View Article : Google Scholar : PubMed/NCBI
28	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
29	Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L, Bai X, Zhang Z, Zhang W, Zhang X and Ye L: miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J Biol Chem. 286:13714–13722. 2011. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP and Wan R: Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol. 67:41–52. 2010. View Article : Google Scholar : PubMed/NCBI
32	Swanson RA and Sharp FR: Infarct measurement methodology. J Cereb Blood Flow Metab. 14:697–698. 1994. View Article : Google Scholar : PubMed/NCBI
33	Ackermann EJ, Conde-Frieboes K and Dennis EA: Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem. 270:445–450. 1995. View Article : Google Scholar : PubMed/NCBI
34	Kalyvas A and David S: Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron. 41:323–335. 2004. View Article : Google Scholar : PubMed/NCBI
35	Myou S, Sano H, Fujimura M, Zhu X, Kurashima K, Kita T, Nakao S, Nonomura A, Shioya T, Kim KP, et al: Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition. Nat Immunol. 2:145–149. 2001. View Article : Google Scholar : PubMed/NCBI
36	Nagase T, Uozumi N, Aoki-Nagase T, Terawaki K, Ishii S, Tomita T, Yamamoto H, Hashizume K, Ouchi Y and Shimizu T: A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 284:L720–L726. 2003. View Article : Google Scholar : PubMed/NCBI
37	Riendeau D, Guay J, Weech PK, Laliberte F, Yergey J, Li C, Desmarais S, Perrier H, Liu S, Nicoll-Griffith D, et al: Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem. 269:15619–15624. 1994.PubMed/NCBI
38	Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, et al: Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 11:1311–1318. 2008. View Article : Google Scholar : PubMed/NCBI
39	Khan M, Shunmugavel A, Dhammu TS, Matsuda F, Singh AK and Singh I: Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats. J Neuroinflammation. 12:942015. View Article : Google Scholar : PubMed/NCBI
40	Nito C, Kamada H, Endo H, Niizuma K, Mye DJ and Chan PH: Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in bolld-brain barrier disruption after focal cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 28:1686–1696. 2008. View Article : Google Scholar : PubMed/NCBI
41	Cramer SC: Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 63:549–560. 2008. View Article : Google Scholar : PubMed/NCBI
42	Cramer SC and Crafton KR: Somatotopy and movement representation sites following cortical stroke. Exp Brain Res. 168:25–32. 2006. View Article : Google Scholar : PubMed/NCBI
43	Bosetti F and Weerasinghe GR: The expression of brain cyclooxygenase-2 is down-regulated in the cytosolic phospholipase A2 knockout mouse. J Neurochem. 87:1471–1477. 2003. View Article : Google Scholar : PubMed/NCBI
44	Sapirstein A, Saito H, Texel SJ, Samad TA, O'Leary E and Bonventre JV: Cytosolic phospholipase A2alpha regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. Am J Physiol Regul Integr Comp Physiol. 288:R1774–R1782. 2005. View Article : Google Scholar : PubMed/NCBI
45	Sevastou I, Kaffe E, Mouratis MA and Aidinis V: Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 1831:42–60. 2013. View Article : Google Scholar : PubMed/NCBI